Board/Management Information • Jan 31, 2019
Board/Management Information
Open in ViewerOpens in native device viewer
PRESS RELEASE • PRESS RELEASE • PRESS RELEASE
MEETING TO BE HELD IN PARIS, FEBRUARY 11TH
Paris and Boston, January 31th, 2019 - 5:45 pm CET - Neovacs (Euronext Paris Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto immune diseases, announces it
Frédéric Houssiau, MD, PhD Vice Rector of the Health Sciences Sector, at the Universit Catholi of
th of February. Prof
Pr Eric Morand, MD, PhD, Head of the School of Clinical Sciences at Monash Health, Monash
Pr Thomas Dörner, MD, Professor of Rheumatology and Hemostaseology at Charité University
Dr Katherine Thanou, MD, Research Affiliate, Arthritis and Clinical Immunology Research
Dr Michael Tee, MD, MHPED, MBA, Vice Chancellor, Medical Center Manila, Rheumatology
Dr Edsel Maurice Salvana, MD, PhD, Director, Institute of Molecular Biology and
his CAB under the Chairmanship of Pr Frédéric Houssiau will support Neovacs in the design of the
About Neovacs
Contacts
NEOVACS – Corporate Communication & Investor Relations Charlène Masson
NEWCAP- Media Annie-Florence Loyer
Léa Jacquin
ORPHEON FINANCE – Financial Communication and Investor Relations James Palmer
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.